Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories reports that its partner Immutep has halted the TACTI-004 Phase III trial of Eftilagimod alfa in first-line non-small cell lung cancer. An independent data monitoring committee recommended discontinuation after a planned interim futility analysis reviewing safety and efficacy data.
Enrollment in the study will stop and Immutep will wind down the trial while following patients and closing sites. Dr. Reddy’s subsidiary, which holds exclusive rights to develop and commercialize Eftilagimod alfa in many territories outside North America, Europe, Japan and Greater China, has so far made only the upfront payment under the collaboration and is in discussions with Immutep on the path forward.
Dr. Reddy’s Laboratories Limited reported the allotment of 10,275 equity shares of Re.1 each on March 12, 2026 to eligible employees who exercised stock options under its 2002 ESOP and 2007 ADR stock option schemes.
Following this issuance, total issued shares are stated as 83,46,54,295, and total issued share capital is Rs. 83,46,54,295/-. The company notes total paid-up capital of 83,46,53,295 equity shares of Re.1 each, aggregating to Rs. 83,46,53,295/-, with a difference of 1,000 shares due to historical forfeiture in 1988. The newly allotted shares are equity shares that rank pari passu with existing shares.
Dr. Reddy’s Laboratories responded to media reports about a Delhi High Court decision involving Semaglutide products and a dispute with Novo Nordisk. The company explains that the court’s Division Bench upheld an earlier order allowing it to manufacture Semaglutide in India and export it to countries where Novo Nordisk does not hold a patent registration, while refusing an interim injunction on Semaglutide products. Dr. Reddy’s emphasizes that the litigation remains sub judice and that, in its view, there is currently no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.
Dr. Reddy’s Laboratories Limited has approved a key senior leadership change. Based on the Nomination, Governance and Compensation Committee’s recommendation, the Board has elevated M S Madhu Sundar, currently Head Global Manufacturing FTO Oral Solid Dosages and Operational Excellence, to Global Head of Quality and PV, Senior Management Personnel and Member of the Management Council, effective April 1, 2026.
Madhu Sundar brings 28 years of industrial experience in API and dosage form manufacturing, quality, regulatory affairs and supply chain, and joined the company in October 2017. The company is also revising roles of other senior leaders from April 1, 2026, including appointing M V Ramana as CEO Global Generics, Sanjay Sharma as Chief Operating Officer, Krishna Venkatesh as Global Head of IPDO, and Patrick Aghanian as Head – Consumer Health Organization.
Dr. Reddy’s Laboratories Limited reports that the U.S. Department of Justice has closed its inquiry into alleged improper payments to healthcare professionals under the Foreign Corrupt Practices Act and has not recommended any enforcement action against the company. This follows an earlier letter from the U.S. Securities and Exchange Commission stating it had concluded a related investigation and did not intend to recommend enforcement. These outcomes relate to an anonymous complaint first disclosed in 2020 and formally notified to U.S. and Indian regulators, and they remove the risk of FCPA enforcement actions based on the investigated matters.
Dr. Reddy’s Laboratories Limited reports the outcome of a United States Food & Drug Administration inspection at its formulations manufacturing facility FTO-SEZ PU01 in Srikakulam, Andhra Pradesh. The company has received the Establishment Inspection Report on March 4, 2026.
The USFDA classified the inspection outcome as “Voluntary Action Indicated (VAI)” and stated that the inspection is officially closed under 21 CFR 20.64(d)(3). This update follows an earlier intimation dated December 12, 2025 about the same GMP and Pre-Approval Inspection.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its upcoming schedule of analyst and institutional investor meetings. The company’s management plans to participate in two group meetings with investors in early March 2026.
On March 4, 2026, management will attend an in-person group meet organized by Ambit Capital in Hyderabad from 11:00 to 13:30 IST. On March 5, 2026, they will join a virtual group meet organized by Goldman Sachs from 11:15 to 12:15 IST. The company notes that this schedule may change due to any exigencies on the part of investors or the company.
Dr. Reddy’s Laboratories Limited reports that the U.S. Securities and Exchange Commission has concluded its investigation into earlier anonymous allegations of improper payments to healthcare professionals in Ukraine and other markets. The SEC’s letter dated February 23, 2026 states it does not intend to recommend any enforcement action against the company at this time.
The company notes that the SEC’s communication, issued under Securities Act Release No. 5310, should not be read as an exoneration or a guarantee that no action will ever result, but it does indicate that the current investigation is being closed without an enforcement recommendation.
Dr. Reddy’s Laboratories has agreed to acquire the Indian trademarks and related assets of hormone replacement therapy brands Progynova® and Cyclo‑Progynova® from Mercury Pharma Group Limited for USD 32.15 million.
Progynova®, an estradiol valerate therapy, is described as the #1 brand in the estradiol represented pharmaceutical market in India and recorded sales of INR 100 crore as per IQVIA MAT December 2025. Cyclo‑Progynova® combines estradiol valerate and norgestrel for estrogen deficiency symptoms treatment.
The deal is not a related‑party transaction and is intended to strengthen Dr. Reddy’s gynecology portfolio in India and mark a strategic entry into the hormone replacement therapy segment.
Dr. Reddy’s Laboratories Limited has allotted 12,665 equity shares of Re.1 each on February 17, 2026 to eligible employees following the exercise of stock options. These options were granted under the Dr. Reddy’s Employees Stock Options Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007.
The shares were exercised at prices ranging from Re.1 to Rs. 735.80 per share, and the new shares rank pari passu with existing equity shares. After this allotment, total issued shares are 83,46,44,020 and total issued share capital is Rs. 83,46,44,020, with paid-up capital of 83,46,43,020 equity shares of Re.1 each.